

NMSB2

January 19, 2007

CERTIFIED MAIL, RETURN RECEIPT REQUESTED

Division of Nuclear Materials Safety U.S. Nuclear Regulatory Commission Region I 475 Allendale Road King of Prussia, PA 19406

03036603

Subject:

Notification of Decommissioning USNRC License No. 37-30924-01 TetraLogic Pharmaceuticals IES Project No. EHS07564.02 2007 JAN 24 PN 12: 21

To Whom It May Concern:

TetraLogic Pharmaceuticals (TetraLogic) has retained IES Engineers (IES) for the purpose of supervising and documenting the decommissioning of the laboratory facility located at 365 Phoenixville Pike in Malvern, Pennsylvania. TetraLogic is decommissioning because they are moving from 365 Phoenixville Pike to 343 Phoenixville Pike. Please note TetraLogic will not be terminating this license. Rather the new address will be added to the license.

The 365 facility operated under Standard Industrial Classification (SIC) Code 8731 – Research and Development. TetraLogic is a biopharmaceutical company that discovers and develops drugs to treat cancer. TetraLogic is approved for use of ³H, ¹⁴C, ³²P, ³³P and ³⁵S. TetraLogic used only ³H at the 365 Phoenixville Pike address and has not used RAM onsite since late May 2005.

Facility swipes and related decommissioning were completed upon termination of RAM work in June 2004. Facility decommissioning in preparation for the move has begun at 365 Phoenixville Pike. Due to the nature of use onsite and the minimal quantities used, decommissioning of the limited RAM use areas will only require efforts currently covered under the materials license.

A radioactive materials waste pick up occurred on June 1, 2005. At that time all radioactive materials were removed from the site. As there has been no radioactive material use since and because decommissioning occurred at that time, TetraLogic does not expect to generate any RAM waste during final decommissioning.

Pursuant to the requirements of 10 CFR 30.36D, TetraLogic is notifying the NRC of our intent to decommission the facility located at 365 Phoenixville Pike in Malvern, Pennsylvania. Decommissioning activities will continue until decommissioning is complete. TetraLogic is scheduled to move from the facility by the end of this month.

139999

NIASS/RGNI MATERIALS-032

Division of Nuclear Materials Safety January 19, 2007 Page 2

TetraLogic will request under separate header the addition of the new address to the existing license.

Should you have any questions regarding the above material, please do not hesitate to contact Ms. Jessica Leonard, our Radiation Safety Consultant at 610-828-3078 or me.

Sincerely,

Mark. McKinlay Chief Scientific Officer

cc: S. Chunduru, TetraLogic

A. Greene, TetraLogic

J. Leonard, IES

G. Petroka, IES

This is to acknowledge the receipt of your letter/application dated	
includes an administrative review	and to inform you that the initial processing which has been performed.
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.	
Please provide to this office within 30 days of your receipt of this card	
A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.	
Your action has been assigned Mail Control Number 13 F8 95 When calling to inquire about this action, please refer to this control number. You may call us on (610) 337-5398, or 337-5260.	
NRC FORM 532 (RI) (6-96)	Sincerely, Licensing Assistance Team Leader